BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32350628)

  • 1. Biology and Treatment of Hairy Cell Leukemia.
    Paillassa J; Troussard X
    Curr Treat Options Oncol; 2020 Apr; 21(6):44. PubMed ID: 32350628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hairy cell leukemia.
    Chihara D; Kreitman RJ
    Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hairy cell leukemia: present and future directions.
    Kreitman RJ
    Leuk Lymphoma; 2019 Dec; 60(12):2869-2879. PubMed ID: 31068044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
    Troussard X; Maître E; Cornet E
    Am J Hematol; 2022 Feb; 97(2):226-236. PubMed ID: 34710243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
    Maitre E; Cornet E; Troussard X
    Am J Hematol; 2019 Dec; 94(12):1413-1422. PubMed ID: 31591741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
    Troussard X; Maître E; Paillassa J
    Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.
    Troussard X; Cornet E
    Am J Hematol; 2017 Dec; 92(12):1382-1390. PubMed ID: 29110361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoconjugates and new molecular targets in hairy cell leukemia.
    Kreitman RJ
    Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on hairy cell leukemia.
    Kreitman RJ; Arons E
    Clin Adv Hematol Oncol; 2018 Mar; 16(3):205-215. PubMed ID: 29742076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutic options for relapsed hairy cell leukemia.
    Jain P; Polliack A; Ravandi F
    Leuk Lymphoma; 2015; 56(8):2264-72. PubMed ID: 25563425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
    Kreitman RJ; Arons E
    Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
    Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
    J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
    Falini B; Martelli MP; Tiacci E
    Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
    Kreitman RJ; Pastan I
    Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
    Tiacci E; De Carolis L; Simonetti E; Capponi M; Ambrosetti A; Lucia E; Antolino A; Pulsoni A; Ferrari S; Zinzani PL; Ascani S; Perriello VM; Rigacci L; Gaidano G; Della Seta R; Frattarelli N; Falcucci P; Foà R; Visani G; Zaja F; Falini B
    N Engl J Med; 2021 May; 384(19):1810-1823. PubMed ID: 33979489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hairy Cell Leukaemia.
    Cross M; Dearden C
    Curr Oncol Rep; 2020 Apr; 22(5):42. PubMed ID: 32297104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoconjugates in the management of hairy cell leukemia.
    Kreitman RJ; Pastan I
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights in the management of patients with hairy cell leukemia.
    Cornet E; Damaj G; Troussard X
    Curr Opin Oncol; 2015 Sep; 27(5):371-6. PubMed ID: 26154707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hairy cell leukemia: Update on molecular profiling and therapeutic advances.
    Grever MR; Blachly JS; Andritsos LA
    Blood Rev; 2014 Sep; 28(5):197-203. PubMed ID: 25110197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.